Analyst Price Target is $11.00
▲ +250.32% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Satsuma Pharmaceuticals in the last 3 months. The average price target is $11.00, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 250.32% upside from the last price of $3.14.
Current Consensus is
The current consensus among 3 polled investment analysts is to buy stock in Satsuma Pharmaceuticals. This rating has held steady since July 2020, when it changed from a Hold consensus rating.
Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company's lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can be self-administered with proprietary pre-filled, single-use, and nasal delivery device. Satsuma Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.